Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 81-89 , January 2006

Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin

  • Moustapha E. Moustapha

      Affiliations

    • Department of Chemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • University of Missouri Research Reactor (MURR), University of Missouri-Columbia, Columbia, MO 65211, USA
    • ,
  • Gary J. Ehrhardt

      Affiliations

    • Department of Chemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • University of Missouri Research Reactor (MURR), University of Missouri-Columbia, Columbia, MO 65211, USA
    • ,
  • Charles J. Smith

      Affiliations

    • Department of Radiology, University of Missouri-Columbia, Columbia, MO 65211, USA
    • University of Missouri Research Reactor (MURR), University of Missouri-Columbia, Columbia, MO 65211, USA
    • Research Services, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Lawrence P. Szajek

      Affiliations

    • Positron Emission Tomography Department, National Institutes of Health, Bethesda, MD 20892-1180, USA
    • ,
  • William C. Eckelman

      Affiliations

    • Positron Emission Tomography Department, National Institutes of Health, Bethesda, MD 20892-1180, USA
    • ,
  • Silvia S. Jurisson

      Affiliations

    • Department of Chemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 573 882 2107.

Received 24 August 2005 ,Revised 28 September 2005 ,Accepted 29 September 2005.

References 

  1. Saha GB. In: Fundamentals of nuclear pharmacy. 3rd ed.. New York: Springer-Verlag; 1992;p. 31–45
  2. Page M. In: Tumor targeting in cancer therapy. Totowa (NJ): Humanan Press; 2002;p. 257–275
  3. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property considerations. J Nucl Med. 1991;32:174–185
  4. Goldenberg DM. Cancer therapy with radiolabeled antibodies. Boca Raton (Fla): CRC Press Inc.; 1995;
  5. Larson SM. Radioimmunology. Imaging and therapy. Cancer. 1991;67:1253–1260
  6. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev. 1999;99:2269–2292
  7. Jia W, Ehrhardt GJ. Production of Re-188 and Re-186 via Inorganic Szilard-Chalmers, U.S. Process, Patent 6,222,896 (1998).
  8. Kobayashi K, Motoishi S, Terunuma K, Rauf AA, Hashimoto K. Production of 186Re and 188Re, and Synthesis of 188Re-DTPA. In: JAERI-Conf (1999), 99-006 (Proceedings of the Sixth Asian Symposium on Research Reactors, Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibraki, Japan; 1999). 1999;p. 232–237
  9. Ehrhardt GJ, Blumer ME, Su FM, Vanderheyden JL, Fritzberg AR. Experience with aluminum perrhenate targets for reactor production of high specific activity Re-186. Appl Radiat Isot. 1997;48:1–4
  10. Qaim SM. 2nd school and workshop on cyclotrons and applications. Cairo (Egypt): Egyptian Atomic Energy Authority; 1997;
  11. Vera Ruiz H, Lambrecht RM. Cyclotrons and their applications. In: Proceedings of the International Conference on Cyclotrons and their Applications, Caen, France, June 14–19. 1998;
  12. Nozaki T, Hazue M. Advantage of accelerator produced radionuclides. In:  Wagner HN,  Szabo Z,  Buchanan JW editor. Principles of nuclear medicine. 2nd ed.. Philadelphia: W. B. Saunders; 1995;p. 144–150
  13. Robinson JR. Radiochemical processing of activated targets. In:  Helus F editors. Radionuclide production. Boca Raton (Fla): CRC Press; 1983;p. 121–138
  14. Shigeta N, Matsuoka H, Osa A, Koizumi M, Izumo M, Kobayashi K, et al. Production of no-carrier-added 186Re. J Radioanal Nucl Chem. 1996;205:85–92
  15. Zhang X, Li Q, Li W, Sheng R, Shen S. Production of no-carrier-added 186Re via deuteron induced reactions on isotopically enriched 186W. Appl Radiat Isot. 2001;54:89–92
  16. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003;30:861–868
  17. Smith CJ, Gali H, Sieckman GL, Higginbothman C, Volkert WA, Hoffman TJ. Radiochemical investigations of 99mTc-N3S-X-BBN[7–14]NH2: an in vitro/in vivo structure–activity relationship study where X=0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem. 2003;93–102
  18. Van de Wilie C, Dumont F, Broecke RV, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualization of GRP receptor expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694–1699
  19. Wong E, Fauconnier T, Bennett S, Valliant J, Nguyen T, Lau F, et al. Rhenium(V) and technetium(V) oxo complexes of an N(2)N'S peptidic chelator: evidence of interconversion between the syn and anti conformations. Inorg Chem. 1997;36:5799–5808

PII: S0969-8051(05)00259-3

doi: 10.1016/j.nucmedbio.2005.09.006

Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 81-89 , January 2006

Article Tools

* Image Usage & Resolution